
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is a late-stage development biopharmaceutical company, primarily focused on researching and developing new cancer-fighting medicines. With a strong pipeline of novel anticancer agents that inhibit critical signaling pathways in cancer cells, there is strong potential for continued growth and success. Recent commercial results, positive data from clinical trials, and a strengthened balance sheet provide a strong foundation for continued success in the near and long term.
Bears say
Verastem is facing numerous risks, including challenges in R&D, regulatory approval, and commercial success, as well as increasing competition and potential for underwhelming product sales. While the company's current pipeline shows promise, the financial burden of further R&D and dilutive financing could be too much, and the upside potential of their KRAS G12D inhibitor VS-7375 may be limited in a crowded market. The recent change in fair value preferred warrant liability also raises concerns about the company's financial stability.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares